BioSpace News Archive

Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced that Adverum Biotechnologies will present at the following upcoming investor conferences.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference.

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 11:40 AM ET in New York City.

AVITA Medical, Inc. announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (PV).

Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule.

Tyra Biosciences, Inc. today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the America Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.